Macquarie Group Ltd. bought a new stake in Masimo Co. (NASDAQ:MASI) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 5,700 shares of the medical equipment provider’s stock, valued at approximately $493,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Masimo in the 2nd quarter valued at $106,000. DekaBank Deutsche Girozentrale increased its stake in shares of Masimo by 78.3% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock valued at $182,000 after buying an additional 925 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Masimo by 13.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock valued at $184,000 after buying an additional 236 shares during the period. Advisor Group Inc. increased its stake in shares of Masimo by 38.4% in the 2nd quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock valued at $216,000 after buying an additional 655 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Masimo in the 2nd quarter valued at $219,000. 83.74% of the stock is owned by institutional investors.
Shares of Masimo Co. (MASI) opened at $84.66 on Friday. Masimo Co. has a 52 week low of $64.29 and a 52 week high of $104.71. The company has a market capitalization of $4,410.00, a price-to-earnings ratio of 32.61, a P/E/G ratio of 2.87 and a beta of 0.72.
Several equities research analysts have recently commented on MASI shares. Stifel Nicolaus reissued a “buy” rating and issued a $108.00 target price on shares of Masimo in a research note on Friday, November 3rd. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Thursday, November 2nd. Finally, BidaskClub cut Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $97.17.
In other Masimo news, EVP Yongsam Lee sold 5,000 shares of Masimo stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total transaction of $449,450.00. Following the transaction, the executive vice president now directly owns 74,000 shares in the company, valued at $6,651,860. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the transaction, the director now owns 73,249 shares in the company, valued at $6,592,410. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,074 shares of company stock valued at $4,737,245. 16.60% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://sportsperspectives.com/2017/12/15/5700-shares-in-masimo-co-masi-acquired-by-macquarie-group-ltd.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.